CYP2C19 and coronary artery disorder: CYP2C19 is a key clopidogrel-metabolizing enzyme, and there is a strong association between CYP2P19*2 polymorphism and clopidogrel resistance in patients with coronary heart disease (CHD) (Sun et al., 2020).